Global Amylin Analog Market, By Diabetes Type (Type I Diabetes, Type II Diabetes, Gestational Diabetes), Drug Type (Pramlintide, Others), Dosage (Injectables, Others), Route of Administration (Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the amylin analog? market is anticipated to grow rapidly during the forecast period owing to the rising prevalence of diabetes. Amylin is a peptide hormone that is produced by pancreatic beta cells and is therefore lacking in diabetics. The hormone promotes satiety by delaying stomach emptying. It also helps insulin control elevated glucose levels after a meal. Amylin analogues are injectable medicines that are used to treat Type I and Type II diabetes. Hence this led to the high demand of amylin analog in the market.
Data Bridge Market Research analyses that the amylin analog? market was valued at USD 522.75 million in 2021 and is expected to reach USD 796.19 million by 2029, registering a CAGR of 5.40% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Diabetes is treated with amylin analogues. Amylin and amylin analogues exhibit qualities that are similar to physiological amylin. Amylin analogues are given as a subcutaneous injection before meals. These are stable synthetic chemicals. Along with insulin, the pancreas' beta cells secrete amylin. Amylin is a 37-amino-acid polypeptide neuroendocrine hormone that suppresses food intake, delays gastric emptying, regulates blood pressure via the renin-angiotensin system, and inhibits glucagon secretion to give the impression of being full or totally satiated.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diabetes Type (Type I Diabetes, Type II Diabetes, Gestational Diabetes), Drug Type (Pramlintide, Others), Dosage (Injectables, Others), Route of Administration (Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (UK), Sanofi (France), Novo Nordisk A/S (Denmark), Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (US), Biocon (India)
|
|
Market Opportunities
|
|
Amylin Analog? Market Dynamics
Drivers
- Increasing prevalence of diabetes
The rising prevalence of diabetes is a primary driver of the amylin analog? market's growth. A major reason driving the growth of the amylin analogues market is the growing burden of diabetes on industrialised economies around the world, as a result of their role as global players, and the consequent demand for sophisticated therapeutic medications to treat it.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of amylin analog? market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness about diabetes, its type, treatment and causes will expand the amylin analog? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of amylin analog? market. Along with this, rising geriatric population and surging prevalence of obesity will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the amylin analog? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
- Rising adoption rate of e-commerce
Using e-commerce as an alternative to traditional pharmacy stores during COVID-19 and beyond is anticipated to boost sales of amylin analogues since an Omni channel strategy can give customers with service levels that exceed their expectations. This will further enhance the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the amylin analog? market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the amylin analog? market. Additionally, strict guidelines as well as regulations and side effects of amylin analog? such as headache, nausea, vomiting, low blood sugar and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This amylin analog? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the amylin analog? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Amylin analog? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Amylin Analog? Market
Pharmaceutical sector in coordination with governments are trying to combat the COVID-19 pandemic, from vaccine development to pharmaceutical supply chain planning. Furthermore, hydroxychloroquine regularly used medications have seen a tremendous increase for the treatment of COVID-19. Due to the enormous demand for these treatments, manufacturers of COVID-19 management drugs have a lot of prospects, as many wealthy countries are running out of them. As a consequence of the large requirement for vaccines as well as treatment medications for COVID-19, the pharmaceutical and biotechnology sector are anticipated to rise significantly in the coming years. Hence, the market for amylin analogues is projected to be significantly impacted.
Recent Development
- In November 2021, Zealand Pharma had announced the first subject dosed in Phase 1 trial of amylin analogue ZP8396 for the treating of obesity. ZP8396 is a strong long-acting amylin analogue that has been developed to improve solubility, reduce fibrillation, and allow co-formulation with other peptides, particularly GLP-1 analogues. Amylin analogues have the potential to be used as single or combined treatments for obesity.
Global Amylin Analog? Market Scope
The amylin analog? market is segmented on the basis of diabetes type, drug type, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diabetes Type
- Type I Diabetes
- Type II Diabetes
- Gestational Diabetes
On the basis of diabetes type, the global hepatic drugs market is segmented into type I diabetes, type II diabetes, and gestational diabetes.
Drug Type
- Pramlintide
- Others
On the basis of drug type, the global hepatic drugs market is segmented into pramlintide and others.
Dosage
- Injectables
- Others
On the basis of dosage, the amylin analog? market is segmented into injectables and others.
Route of Administration
- Subcutaneous
- Others
The route of administration segment for the amylin analog? market is segmented into subcutaneous and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the amylin analog? market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the amylin analog? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Amylin Analog? Market Regional Analysis/Insights
The Amylin analog? market is analysed and market size insights and trends are provided by country, diabetes type, drug type, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Amylin analog? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the amylin analog? market because of the growing number of patients suffering from diabetes in this region. Additionally, rising prevalence of obesity and growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Furthermore, growing prevalence of obesity will further propel the market’s growth rate in this region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Amylin Analog? Market Share Analysis
The Amylin analog? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to amylin analog? market.
Some of the major players operating in the amylin analog? market are:
- AstraZeneca (UK)
- Boehringer Ingelheim International GmbH. (Germany)
- Sanofi (France)
- Novo Nordisk A/S (Denmark)
- Bristol-Myers Squibb Company (US)
- Biocon (India)
SKU-